Back to Search
Start Over
Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications
- Source :
- Emerging Infectious Diseases, vol 28, iss 3
- Publication Year :
- 2022
- Publisher :
- Centers for Disease Control and Prevention (CDC), 2022.
-
Abstract
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys can estimate cumulative incidence for monitoring epidemics, requiring assessment of serologic assays to inform testing algorithm development and interpretation of results. We conducted a multilaboratory evaluation of 21 commercial high-throughput SARS-CoV-2 serologic assays using blinded panels of 1,000 highly characterized specimens. Assays demonstrated a range of sensitivities (96%-63%), specificities (99%-96%), and precision (intraclass correlation coefficient 0.55-0.99). Durability of antibody detection was dependent on antigen and immunoglobulin targets; antispike and total Ig assays demonstrated more stable longitudinal reactivity than antinucleocapsid and IgG assays. Assays with high sensitivity, specificity, and durable antibody detection are ideal for serosurveillance, but assays demonstrating waning reactivity are appropriate for other applications, including correlation with neutralizing activity and detection of anamnestic boosting by reinfections. Assay performance must be evaluated in context of intended use, particularly in the context of widespread vaccination and circulation of SARS-CoV-2 variants.
- Subjects :
- Microbiology (medical)
SARS-CoV-2
Epidemiology
COVID-19
Antibodies, Viral
Sensitivity and Specificity
Antibodies
zoonoses
respiratory infections
serologic assays
vaccine-preventable diseases
Infectious Diseases
coronavirus disease
Humans
viruses
Serologic Tests
Viral
severe acute respiratory syndrome coronavirus 2
Subjects
Details
- ISSN :
- 10806059 and 10806040
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Emerging Infectious Diseases
- Accession number :
- edsair.doi.dedup.....19ea727991434e9125b45ef63d60dc9e